Statement of Beneficial Ownership (sc 13d)
February 23 2018 - 12:54PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
Vican
Resources, Inc.
(Name
of Issuer)
Common
Stock
(Title
of Class of Securities)
925606105
(CUSIP
Number)
Julia Kline, Esq.
General Counsel
Vican Resources,
Inc.
2600 W. Executive Pkwy., Ste. 500
Lehi, UT 84043
Tel. (435) 315-2457
(Name,
Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January
31, 2018
(Date
of Event which Requires Filing of this Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]
Note
:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7
for other parties to whom copies are to be sent.
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect
to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 925606303
|
13D
|
Page
2
of 4 Pages
|
|
|
|
|
|
1.
|
|
NAMES
OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
GREGORY MONGEON
|
|
|
2.
|
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) [ ]
(b) [ ]
|
|
|
3.
|
|
SEC
USE ONLY
|
|
|
4.
|
|
SOURCE
OF FUNDS (see instructions)
N/A
|
|
|
5.
|
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
[ ]
|
|
|
6.
|
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
N/A
|
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
|
7.
|
|
SOLE
VOTING POWER
N/A
|
|
8.
|
|
SHARED
VOTING POWER
N/A
|
|
9.
|
|
SOLE
DISPOSITIVE POWER
N/A
|
|
10.
|
|
SHARED
DISPOSITIVE POWER
N/A
|
11.
|
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,500,000 Common Stock shares
|
|
|
12.
|
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) [ ]
|
|
|
13.
|
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
21.21%
|
|
|
14.
|
|
TYPE
OF REPORTING PERSON (see instructions)
IN
|
|
|
CUSIP No. 925606303
|
13D
|
Page
3
of 4 Pages
|
Item
1. Security and Issuer.
Common
Stock - Vican Resources, Inc.
Item
2. Identity and Background.
|
(a)
|
GREGORY
MONGEON
|
|
|
|
|
(b)
|
2101
W. Golden Pond Way
|
|
|
Orem,
UT 84058
|
|
|
|
|
(c)
|
Chief
Medical Officer and Director
|
|
|
Vican
Resources, Inc.
|
|
|
2600
W. Executive Drive, Suite 500
|
|
|
Lehi,
UT 84043
|
|
|
|
|
(d)
|
no
criminal convictions
|
Item
3. Source or Amount of Funds or Other Consideration.
Securities
issued in exchange for services rendered as Chief Medical Officer and Chief Sales Officer, pursuant to an employment agreement
with the Issuer dated on or about January 19, 2018.
Item
4. Purpose of Transaction.
Securities
of issuer acquired for investment purpose.
Item
5. Interest in Securities of the Issuer.
|
(a)
|
Gregory
Mongeon - 7,500,000 Common Stock shares (21.21%)
|
|
|
|
|
(b)
|
7,500,000
Common Stock shares.
|
|
|
|
|
(c)
|
N/A
|
Item
6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
N/A
Item
7. Material to Be Filed as Exhibits.
N/A
CUSIP No. 925606303
|
13D
|
Page
4
of 4 Pages
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
GREGORY
MONGEON
|
|
|
|
/s/
Gregory Mongeon
|
|
Gregory
Mongeon
|
|
|
|
Chief
Medical Officer and Director
|
|
|
|
February
23, 2018
|